Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortization of Deferred ChargesAmortizatization of IntangiblesAmortizatization of IntangiblesAsset Writedowns and ImpairmentAsset Writedowns and ImpairmentCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Accured ExpensesChange in Accured ExpensesChange in CashChange in IntangiblesChange in IntangiblesChange in InventoryChange in InventoryChange in ReceivablesChange in ReceivablesChange in TaxesChange in TaxesDeferred TaxesDivestmentsFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesLong-Term Debt IssuancesLong-Term Debt RepaymentsNet Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther Working Capital ChangesOther financing activitiesOther financing activitiesSales of Property, Plant and EquipmentSales of Property, Plant and EquipmentShare-based CompensationShare-based CompensationShares IssuedShort-Term Debt issuances
Growth Metrics
Income Statement
Others
Ratios

Cresco Labs (CRLBF) Asset Writedowns and Impairment (2020 - 2026)

Cresco Labs filings provide 7 years of Asset Writedowns and Impairment readings, the most recent being $741000.0 for Q1 2026.

  • On a quarterly basis, Asset Writedowns and Impairment fell 17.85% to $741000.0 in Q1 2026 year-over-year; TTM through Mar 2026 was $104.9 million, a 6353.87% increase, with the full-year FY2025 number at -$1.2 million, down 150.22% from a year prior.
  • Asset Writedowns and Impairment hit $741000.0 in Q1 2026 for Cresco Labs, down from $93.5 million in the prior quarter.
  • In the past five years, Asset Writedowns and Impairment ranged from a high of $139.4 million in Q4 2022 to a low of -$2.5 million in Q2 2024.
  • Median Asset Writedowns and Impairment over the past 5 years was $1.2 million (2022), compared with a mean of $25.0 million.
  • Biggest five-year swings in Asset Writedowns and Impairment: skyrocketed 23147.94% in 2023 and later tumbled 112.59% in 2024.
  • Cresco Labs' Asset Writedowns and Impairment stood at $139.4 million in 2022, then plummeted by 99.98% to $24000.0 in 2023, then crashed by 337.5% to -$57000.0 in 2024, then soared by 164084.21% to $93.5 million in 2025, then crashed by 99.21% to $741000.0 in 2026.
  • The last three reported values for Asset Writedowns and Impairment were $741000.0 (Q1 2026), $93.5 million (Q4 2025), and $2.4 million (Q3 2025) per Business Quant data.